Rappta Therapeutics
VerifiedWorking on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A).
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$40—59m (Dealroom.co estimates Oct 2020.)
Company register number 2988325-7
Helsinki Uusimaa (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
€9.0m | Series A | ||
| Total Funding | 000k | ||